JP2005508380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508380A5 JP2005508380A5 JP2003542128A JP2003542128A JP2005508380A5 JP 2005508380 A5 JP2005508380 A5 JP 2005508380A5 JP 2003542128 A JP2003542128 A JP 2003542128A JP 2003542128 A JP2003542128 A JP 2003542128A JP 2005508380 A5 JP2005508380 A5 JP 2005508380A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- linear
- aryl
- aralkyl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 112
- 125000003118 aryl group Chemical group 0.000 claims description 72
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 70
- 125000001475 halogen functional group Chemical group 0.000 claims description 58
- 125000001424 substituent group Chemical group 0.000 claims description 54
- 229910052739 hydrogen Inorganic materials 0.000 claims description 52
- 239000001257 hydrogen Substances 0.000 claims description 52
- 125000003545 alkoxy group Chemical group 0.000 claims description 46
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 46
- 125000001188 haloalkyl group Chemical group 0.000 claims description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 43
- 125000002947 alkylene group Chemical group 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000004450 alkenylene group Chemical group 0.000 claims 23
- 125000002993 cycloalkylene group Chemical group 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 20
- 125000004419 alkynylene group Chemical group 0.000 claims 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 241000124008 Mammalia Species 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 7
- 208000023275 Autoimmune disease Diseases 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 6
- 229920000858 Cyclodextrin Polymers 0.000 claims 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 5
- 150000003536 tetrazoles Chemical class 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 150000004702 methyl esters Chemical class 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010065899 Tracheal inflammation Diseases 0.000 claims 2
- 206010044302 Tracheitis Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000005488 Capillary Leak Syndrome Diseases 0.000 claims 1
- 206010007513 Cardiac aneurysm Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 claims 1
- 206010018785 Gingival infections Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 208000031932 Systemic capillary leak syndrome Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010044541 Traumatic shock Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002619 cancer immunotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000019258 ear infection Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000001875 irritant dermatitis Diseases 0.000 claims 1
- 208000023569 ischemic bowel disease Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 0 C*(C)C(C(C)S1)OC1=O Chemical compound C*(C)C(C(C)S1)OC1=O 0.000 description 5
- LWLOKSXSAUHTJO-UHFFFAOYSA-N CC(C(C)O1)OC1=O Chemical compound CC(C(C)O1)OC1=O LWLOKSXSAUHTJO-UHFFFAOYSA-N 0.000 description 2
- SWMIQHDRPJPYJM-UHFFFAOYSA-N CC(C(C(C)(C)C)N1)OC1=O Chemical compound CC(C(C(C)(C)C)N1)OC1=O SWMIQHDRPJPYJM-UHFFFAOYSA-N 0.000 description 1
- ZDXCVVOLHJFBMT-UHFFFAOYSA-N CC(C(C(C)(C)C)S1)SC1=O Chemical compound CC(C(C(C)(C)C)S1)SC1=O ZDXCVVOLHJFBMT-UHFFFAOYSA-N 0.000 description 1
- FEVSXQMJLWVHDA-UHFFFAOYSA-N CC(C(C)N1)NC1=O Chemical compound CC(C(C)N1)NC1=O FEVSXQMJLWVHDA-UHFFFAOYSA-N 0.000 description 1
- DXRZFYKVFKAPCE-UHFFFAOYSA-N CC(C(C)O1)NC1=O Chemical compound CC(C(C)O1)NC1=O DXRZFYKVFKAPCE-UHFFFAOYSA-N 0.000 description 1
- BQNBCJVFHWANQK-UHFFFAOYSA-N CC(C(C)S1)OC1=O Chemical compound CC(C(C)S1)OC1=O BQNBCJVFHWANQK-UHFFFAOYSA-N 0.000 description 1
- CQUCRFYNCROOIS-UHFFFAOYSA-N CC(C(C)S1)SC1=O Chemical compound CC(C(C)S1)SC1=O CQUCRFYNCROOIS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33868401P | 2001-11-06 | 2001-11-06 | |
| PCT/US2002/035318 WO2003040080A2 (en) | 2001-11-06 | 2002-11-05 | Lipoxin a4 analogs |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009035743A Division JP5065315B2 (ja) | 2001-11-06 | 2009-02-18 | リポキシンａ４類似体 |
| JP2009142783A Division JP4510919B2 (ja) | 2001-11-06 | 2009-06-15 | リポキシンａ４類似体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508380A JP2005508380A (ja) | 2005-03-31 |
| JP2005508380A5 true JP2005508380A5 (enExample) | 2009-04-09 |
Family
ID=23325714
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003542128A Withdrawn JP2005508380A (ja) | 2001-11-06 | 2002-11-05 | リポキシンａ４類似体 |
| JP2009035743A Expired - Fee Related JP5065315B2 (ja) | 2001-11-06 | 2009-02-18 | リポキシンａ４類似体 |
| JP2009142783A Expired - Fee Related JP4510919B2 (ja) | 2001-11-06 | 2009-06-15 | リポキシンａ４類似体 |
| JP2012125762A Expired - Fee Related JP5457501B2 (ja) | 2001-11-06 | 2012-06-01 | リポキシンａ４類似体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009035743A Expired - Fee Related JP5065315B2 (ja) | 2001-11-06 | 2009-02-18 | リポキシンａ４類似体 |
| JP2009142783A Expired - Fee Related JP4510919B2 (ja) | 2001-11-06 | 2009-06-15 | リポキシンａ４類似体 |
| JP2012125762A Expired - Fee Related JP5457501B2 (ja) | 2001-11-06 | 2012-06-01 | リポキシンａ４類似体 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US6831186B2 (enExample) |
| EP (1) | EP1472209B1 (enExample) |
| JP (4) | JP2005508380A (enExample) |
| KR (1) | KR100958216B1 (enExample) |
| CN (2) | CN1612852A (enExample) |
| AR (1) | AR037252A1 (enExample) |
| AT (1) | ATE424380T1 (enExample) |
| AU (1) | AU2002348167B2 (enExample) |
| BR (1) | BR0213940A (enExample) |
| CA (3) | CA2706872C (enExample) |
| CO (1) | CO5580762A2 (enExample) |
| CY (1) | CY1110472T1 (enExample) |
| DE (1) | DE60231435D1 (enExample) |
| DK (1) | DK1472209T3 (enExample) |
| EC (1) | ECSP085137A (enExample) |
| ES (1) | ES2323769T3 (enExample) |
| IL (2) | IL161811A0 (enExample) |
| MX (1) | MXPA04004300A (enExample) |
| NO (1) | NO329004B1 (enExample) |
| NZ (1) | NZ532672A (enExample) |
| PE (1) | PE20030566A1 (enExample) |
| PL (1) | PL207597B1 (enExample) |
| PT (1) | PT1472209E (enExample) |
| RS (1) | RS51005B (enExample) |
| RU (1) | RU2382026C2 (enExample) |
| SI (1) | SI1472209T1 (enExample) |
| TW (1) | TWI331992B (enExample) |
| UY (1) | UY27531A1 (enExample) |
| WO (1) | WO2003040080A2 (enExample) |
| ZA (1) | ZA200404393B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1441715B1 (en) * | 2001-11-06 | 2013-02-27 | The Brigham And Women's Hospital, Inc. | Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
| US6831186B2 (en) * | 2001-11-06 | 2004-12-14 | Schering Aktiengesellschft | Lipoxin A4 analogs |
| US7327448B2 (en) * | 2004-07-29 | 2008-02-05 | Optech Ventures Llc | Laser-ultrasonic detection of flip chip attachment defects |
| US20060154981A1 (en) * | 2005-01-12 | 2006-07-13 | Alcon, Inc. | Method of reducing intraocular pressure and treating glaucoma |
| WO2007024589A2 (en) * | 2005-08-24 | 2007-03-01 | The Trustees Of Columbia University In The City Of New York | Phagocyte enhancement therapy for atherosclerosis |
| US7687539B1 (en) | 2005-11-07 | 2010-03-30 | Alcon Research, Ltd. | Method of treating ocular allergy |
| TW200816991A (en) * | 2006-08-23 | 2008-04-16 | Bayer Schering Pharma Ag | Treatment and prevention of intestinal fibrosis |
| US8252749B2 (en) * | 2006-09-28 | 2012-08-28 | Follica, Inc. | Methods, kits, and compositions for generating new hair follicles and growing hair |
| CA2668645A1 (en) * | 2006-11-07 | 2008-05-15 | Alcon Research, Ltd. | Method of treating asthma, allergic rhinitis, and skin disorders |
| US20080182901A1 (en) * | 2006-12-04 | 2008-07-31 | Bayer Schering Pharma Aktiengesellschaft | Crystalline acid of lipoxin A4 analogs and method of making |
| US20090036530A1 (en) * | 2006-12-04 | 2009-02-05 | Bayer Schering Pharma Aktiengesellschaft | Crystalline acid of lipoxin A4 analogs and method of making |
| UY30755A1 (es) * | 2006-12-04 | 2008-07-31 | Bayer Schering Pharma Ag | Sal de potasio cristalina de analogos de lipoxina a4 |
| AU2008254925A1 (en) * | 2007-05-15 | 2008-11-27 | Puretech Ventures | Methods and compositions for treating skin conditions |
| US20090137527A1 (en) * | 2007-09-14 | 2009-05-28 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for modulating immune function |
| CA2712970A1 (en) * | 2007-10-29 | 2009-05-07 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Lipoxin a4 protection for retinal cells |
| AU2008318646B2 (en) * | 2007-10-30 | 2014-09-25 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Lipoxin A4 protection for cornea endothelial cells |
| EP2288414A1 (en) * | 2008-05-22 | 2011-03-02 | Bayer Schering Pharma Aktiengesellschaft | Anhydrous and hydrate forms of crystalline 2- ( (2s, 3r, 4e, 6e, 1oe, 12s) -13- (4-fluorophenoxy) -2,3, 12- (trihydroxytrideca-4, 6, 10-trien-8-ynyl) oxy) acetic acid |
| TW201039815A (en) * | 2009-04-13 | 2010-11-16 | Resolvyx Pharmaceuticals Inc | Compositions and methods for the treatment of inflammation |
| US10600073B2 (en) * | 2010-03-24 | 2020-03-24 | Innovid Inc. | System and method for tracking the performance of advertisements and predicting future behavior of the advertisement |
| JP2014500275A (ja) | 2010-12-06 | 2014-01-09 | フォリカ，インコーポレイテッド | 禿頭症を治療するため、および毛髪の成長を促進するための方法 |
| CN104428941B (zh) | 2012-07-13 | 2017-10-13 | 索尔维公司 | 包含三键的氟化的羰基化合物，其制造方法及其用途 |
| WO2018144316A1 (en) | 2017-01-31 | 2018-08-09 | The Brigham And Women's Hospital, Inc. | Alx receptor ligands define a biochemical endotype for inflammation-based diseases |
| EP3870169A4 (en) * | 2018-10-23 | 2022-06-29 | The Brigham and Women's Hospital, Inc. | Lipoxin a4 analogs and uses thereof |
| KR102086298B1 (ko) * | 2019-10-15 | 2020-03-06 | 건국대학교 산학협력단 | 리폭시게나아제 조합반응에 의한 리폭신 유사체의 제조방법 및 이로부터 제조된 리폭신 유사체 |
| CN114890978B (zh) * | 2022-04-19 | 2023-07-25 | 宿迁医美科技有限公司 | 酚类化合物及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650435A (en) | 1991-04-01 | 1997-07-22 | Madara; James L. | Modulation of inflammation related to columnar epithelia |
| US6048897A (en) | 1993-06-15 | 2000-04-11 | Brigham And Women's Hospital | Lipoxin compounds and their use in treating cell proliferative disorders |
| EP0703897B1 (en) | 1993-06-15 | 2008-08-20 | The Brigham And Women's Hospital, Inc. | Lipoxin compounds with prolonged half-life |
| US5441951A (en) * | 1994-06-15 | 1995-08-15 | Brigham & Women's Hospital | Lipoxin compounds |
| AU7215294A (en) | 1993-06-29 | 1995-01-24 | Brigham And Women's Hospital | Modulation of inflammation related to columnar epithelia |
| US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| US6008205A (en) | 1997-04-04 | 1999-12-28 | The Brigham & Women's Hospital, Inc. | Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses |
| EP1163204B1 (en) * | 1999-03-18 | 2005-08-31 | The Brigham And Women's Hospital, Inc. | Lipoxin compounds and their use |
| CA2747376A1 (en) | 1999-03-18 | 2000-09-21 | Brigham And Women's Hospital | Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response |
| CA2645558C (en) | 1999-03-18 | 2012-05-15 | Brigham And Women's Hospital | Regulation of phospholipase d activity |
| AU6382000A (en) | 1999-07-27 | 2001-02-13 | Iowa State University Research Foundation Inc. | Genome analysis |
| DK1228027T3 (da) | 1999-11-09 | 2004-07-19 | Alcon Inc | 3-heteroatomsubstituerede og to carbonhomologe af 15-HETE og fremgangsmåder til anvendelse |
| DK1237549T3 (da) | 1999-11-09 | 2004-06-07 | Alcon Inc | Lipoxin A4 og dets analoger til behandling af törre öjne |
| AU2001249329A1 (en) | 2000-03-20 | 2001-10-03 | Brigham And Women's Hospital | Lipoxin analogs and methods for the treatment of periodontal disease |
| US6831186B2 (en) * | 2001-11-06 | 2004-12-14 | Schering Aktiengesellschft | Lipoxin A4 analogs |
-
2002
- 2002-10-22 US US10/279,084 patent/US6831186B2/en not_active Expired - Lifetime
- 2002-11-05 DK DK02784388T patent/DK1472209T3/da active
- 2002-11-05 CA CA2706872A patent/CA2706872C/en not_active Expired - Fee Related
- 2002-11-05 KR KR1020047006775A patent/KR100958216B1/ko not_active Expired - Fee Related
- 2002-11-05 WO PCT/US2002/035318 patent/WO2003040080A2/en not_active Ceased
- 2002-11-05 PL PL371928A patent/PL207597B1/pl unknown
- 2002-11-05 DE DE60231435T patent/DE60231435D1/de not_active Expired - Lifetime
- 2002-11-05 AT AT02784388T patent/ATE424380T1/de active
- 2002-11-05 RS YUP-384/04A patent/RS51005B/sr unknown
- 2002-11-05 CA CA2706661A patent/CA2706661C/en not_active Expired - Fee Related
- 2002-11-05 SI SI200230826T patent/SI1472209T1/sl unknown
- 2002-11-05 ES ES02784388T patent/ES2323769T3/es not_active Expired - Lifetime
- 2002-11-05 PT PT02784388T patent/PT1472209E/pt unknown
- 2002-11-05 TW TW091132580A patent/TWI331992B/zh not_active IP Right Cessation
- 2002-11-05 RU RU2004117546/04A patent/RU2382026C2/ru not_active IP Right Cessation
- 2002-11-05 EP EP02784388A patent/EP1472209B1/en not_active Expired - Lifetime
- 2002-11-05 BR BR0213940-5A patent/BR0213940A/pt not_active Application Discontinuation
- 2002-11-05 IL IL16181102A patent/IL161811A0/xx active IP Right Grant
- 2002-11-05 CN CNA028268539A patent/CN1612852A/zh active Pending
- 2002-11-05 AU AU2002348167A patent/AU2002348167B2/en not_active Ceased
- 2002-11-05 MX MXPA04004300A patent/MXPA04004300A/es active IP Right Grant
- 2002-11-05 AR ARP020104224A patent/AR037252A1/es not_active Application Discontinuation
- 2002-11-05 NZ NZ532672A patent/NZ532672A/en not_active IP Right Cessation
- 2002-11-05 JP JP2003542128A patent/JP2005508380A/ja not_active Withdrawn
- 2002-11-05 CN CN2007101081453A patent/CN101054344B/zh not_active Expired - Fee Related
- 2002-11-05 CA CA2466418A patent/CA2466418C/en not_active Expired - Fee Related
- 2002-11-06 PE PE2002001079A patent/PE20030566A1/es not_active Application Discontinuation
- 2002-11-06 UY UY27531A patent/UY27531A1/es unknown
-
2004
- 2004-02-18 US US10/782,024 patent/US7223798B2/en not_active Expired - Lifetime
- 2004-05-06 IL IL161811A patent/IL161811A/en not_active IP Right Cessation
- 2004-06-03 CO CO04052090A patent/CO5580762A2/es active IP Right Grant
- 2004-06-03 ZA ZA2004/04393A patent/ZA200404393B/en unknown
- 2004-06-04 NO NO20042336A patent/NO329004B1/no not_active IP Right Cessation
-
2006
- 2006-10-23 US US11/585,501 patent/US7928255B2/en not_active Expired - Lifetime
- 2006-11-03 US US11/592,448 patent/US7994346B2/en not_active Expired - Lifetime
-
2008
- 2008-12-03 EC EC2008005137A patent/ECSP085137A/es unknown
-
2009
- 2009-02-18 JP JP2009035743A patent/JP5065315B2/ja not_active Expired - Fee Related
- 2009-06-04 CY CY20091100596T patent/CY1110472T1/el unknown
- 2009-06-15 JP JP2009142783A patent/JP4510919B2/ja not_active Expired - Fee Related
-
2012
- 2012-06-01 JP JP2012125762A patent/JP5457501B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508380A5 (enExample) | ||
| RU2004117546A (ru) | Аналоги липоксина а4 | |
| TWI609857B (zh) | 經環烷基取代之咪唑衍生物及其用途 | |
| AU2002348167A1 (en) | Lipoxin A4 analogs | |
| JPWO1999019296A1 (ja) | アミノブタン酸誘導体 | |
| JP2018524304A5 (enExample) | ||
| Ohata et al. | Synthesis and Biological Activity of Enantiomeric Pairs of 5-(Alk-2-enyl) thiolactomycin and 5-[(E)-Cycloalk-2-enylidenemethyl] thiolactomycin Congeners | |
| JP2820504B2 (ja) | イソカルバサイクリン誘導体 | |
| JP7205482B2 (ja) | プロスタグランジン誘導体の製造方法 | |
| JP2004123643A (ja) | ω−アリール−α−置換脂肪酸誘導体を含有する糖尿病予防剤、治療剤 | |
| KR20110010755A (ko) | 결정질 2-((2ｓ,3ｒ,4ｅ,6ｅ,10ｅ,12ｓ)-13-(4-플루오로페녹시)-2,3,12-(트리히드록시트리데카-4,6,10-트리엔-8-이닐)옥시)아세트산의 무수물 및 수화물 형태 | |
| HK1109390B (en) | Lipoxin a4 analogs | |
| JPH0892096A (ja) | 血管平滑筋細胞の増殖または遊走阻害剤 | |
| JPH0684305B2 (ja) | イソカルバサイクリン類を活性成分として含有する血中脂質低下剤 | |
| WO1996004903A1 (en) | Vascular smooth muscle cell migration inhibitor | |
| JPWO1994005619A1 (ja) | ４−ヒドロキシ−２−シクロペンテノン誘導体並びにそれを含む制癌剤及び骨形成促進剤 | |
| JPWO2000059865A1 (ja) | ４−アミノブタン酸誘導体およびその誘導体を有効成分とする薬剤 |